Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Regeneron Pharmaceuticals (REGN) through the VizualStocks API.
Revenue from Regeneron's collaboration arrangements recognized during the period, including profit-sharing and reimbursement economics reported in the issuer's revenue disaggregation table. REGN reports this line in U.S. dollars millions.
collaborationRevenueU.S. net product sales of Evkeeza, Regeneron's therapy for homozygous familial hypercholesterolemia, during the period. REGN reports this product-sales line in U.S. dollars millions.
evkeezaUsNetProductSalesU.S. net product sales of EYLEA HD, Regeneron's high-dose aflibercept injection for retinal diseases, during the period. REGN reports this product-sales line in U.S. dollars millions.
eyleaHdUsNetProductSalesU.S. net product sales of legacy EYLEA aflibercept injection during the period, excluding the separate EYLEA HD line after launch. REGN reports this product-sales line in U.S. dollars millions.
eyleaUsNetProductSalesGlobal net product sales of Libtayo, Regeneron's PD-1 oncology antibody, combining U.S. and rest-of-world product sales during the period. REGN reports this total product-sales line in U.S. dollars millions.
libtayoGlobalNetProductSalesRevenue from Regeneron product sales recognized during the period, net of rebates, chargebacks, discounts, distribution-related fees and other sales-related deductions. REGN reports this revenue disaggregation line in U.S. dollars millions.
netProductSalesOther revenue recognized by Regeneron outside net product sales and collaboration revenue, including royalties and other recurring revenue items presented in the issuer's revenue disaggregation table. REGN reports this line in U.S. dollars millions.
otherRevenueU.S. net product sales of Praluent, Regeneron's PCSK9 cholesterol-lowering therapy, during the period. REGN reports this product-sales line in U.S. dollars millions.
praluentUsNetProductSales